RecruitingNot ApplicableNCT05927818
Sentinel Lymph Node Biopsy in Early-Stage Ovarian Cancer
Efficacy of Sentinel Lymph Node Biopsy in Early-Stage Ovarian Cancer
Sponsor
Istanbul University
Enrollment
100 participants
Start Date
Apr 15, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The primary goal of this prospective study is to define the efficacy of the sentinel lymph node biopsy (SLNB) procedure by comparing it to the results obtained from systematic lymphadenectomy, each performed in participants with a suspicious adnexal mass for early-stage ovarian cancer.
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 90 Years
Inclusion Criteria3
- Must have a suspicious adnexal mass for early stage ovarian cancer
- Must be medically and surgically fit enough to perform SLNB and complete the systematic lymphadenectomy.
- \-
Exclusion Criteria7
- Ovarian mass with low probability for early stage ovarian cancer.
- Medical or surgical contraindications for surgical comprehensive staging.
- Metastatic cancers or double primary cancers (metachronous) of ovary
- Recurrent ovarian cancer
- Preoperative or intraoperative finding of advanced ovarian cancer (FİGO stage III and IV)
- Neoadjuvant ovarian cancer
- \-
Interventions
DIAGNOSTIC_TESTSentinel lymph node biopsy (using sterile charcoal stain) in early ovarian cancer
Described in previous sections
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05927818
Related Trials
The Vanguard Study: Testing a New Way to Screen for Cancer
NCT0699589836 locations
National Cancer Institute "Cancer Moonshot Biobank"
NCT04314401152 locations
Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians
NCT072821581 location
ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer
NCT0488992459 locations
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
NCT063214842 locations